Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-4: Copanlisib plus immunochemotherapy in relapsed indolent NHL
CTR20160362Phase 3Terminated
- Sponsor
- Bayer
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of copanlisib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL), Waldenström macroglobulinemia (WM), sponsored by Bayer. Started Mar 2017; status: terminated.
02
Drugs
copanlisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on CTR20160362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160362.